|Day Low/High||83.31 / 85.16|
|52 Wk Low/High||66.02 / 86.36|
DuPont Industrial Biosciences to Expand Research Capabilities in Leiden at New Facility Equipped with Cutting-Edge Biotechnology Laboratories
In an interview with TheStreet, Ackman explains that big investors said they would support him next year if the payroll processor doesn't meet its performance goals.
Bayer's takeover of Monsanto is expected to receive extra scrutiny out of fears the deal could prove detrimental for European farmers.
The chemical giants have finally merged after 18 months of wrestling with various regulators.
Jim Cramer takes his stock picks -- like his fantasy football picks -- very, very seriously.
FMC Corp. is doing great in its two main business segments, Cramer said. That's why FMC stock just got a big upgrade from Bank of America/Merrill Lynch.
Here is an update of what it will mean for our DOW position -- and how we view the combined company.
A stormy session in store?
The two companies will be added to the S&P 500 next week.
We welcome the major change that is upcoming for this long-storied company.
The product can vaporize and kill other crops under certain conditions.
My investing methodology is anticipatory rather than reactionary because I base trades on my fair market value calculations instead of price trends.
Jim Cramer says a well-diversified portfolio is a lot like a well-balanced and winning football team.
Hear me out: The same lessons and disciplines are useful in both.
Meanwhile, the activist hedge fund increased its stake in Snap's foremost competitor.
Strong earnings and guidance lift markets. We drop a couple of names from the portfolio.
FMC Corp is hitting new highs.
The European Commission said Bayer wants to avoid a lengthy review.
Here's what you need to know now.
The S&P continues to trade in one of the tightest ranges we’ve ever seen.
What's next for Dow Chemical CEO Andrew Liveris?
U.S. stock futures rise Monday following a record closing high for the Dow Jones Industrial Average to end last week.
Doug Kass shares his thoughts on the market, and reminds everyone that his diary is not an advice column.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.